Cas:5381-40-8 Aziridine-1-d manufacturer & supplier

We serve Chemical Name:Aziridine-1-d CAS:5381-40-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Aziridine-1-d

Chemical Name:Aziridine-1-d
CAS.NO:5381-40-8
Synonyms:Aziridine-1-d
Molecular Formula:C2H4DN
Molecular Weight:44.07400
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:21.94000
Exact Mass:44.04850
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Aziridine-1-d chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Aziridine-1-d physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Aziridine-1-d Use and application,Aziridine-1-d technical grade,usp/ep/jp grade.


Related News: In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday. Aziridine-1-d manufacturer Some of Amanpour’s counterparts also offered well-wishes on Monday. Aziridine-1-d supplier Some of Amanpour’s counterparts also offered well-wishes on Monday. Aziridine-1-d vendor It was not clear which inquiry – the company’s or the government’s – was launched first and to what extent the subjects coincide. However, as Reuters reported last month, based on three sources familiar with the matter, the Justice Department’s investigation into Lilly includes a review of alleged manufacturing irregularities and records-tampering. Aziridine-1-d factory In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday.